Table of Contents
WASHINGTON – The Consumer Healthcare Products Association (CHPA) today released the below statement following the U.S. Food and Drug Administration’s (FDA) public release of briefing materials for next week’s joint meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee to discuss the supplemental new drug application (sNDA) for OPILL, a daily oral contraceptive:
“CHPA is pleased to see the Rx-to-OTC switch pathway being used once again to evaluate broadened access to beneficial consumer healthcare products,” said David Spangler, CHPA’s SVP of Legal, Government Affairs & Policy. “Should the sponsor’s application ultimately be approved, this switch would be a win-win for both consumers and the entire U.S. healthcare system. Not only does increased access to OTC medicines benefit individuals by empowering them to take greater control over their own health, but OTC access also helps save our healthcare system billions of dollars annually. CHPA looks forward to sharing industry perspectives next week in support of the specific public health and consumer benefits associated with better access to contraceptives.”
